Australia's most trusted
source of pharma news
Friday, 26 April 2024
Posted 1 July 2022 PM
Minister for Health, Mark Butler, has kicked off July announcing the new PBS listings but appears to have tripled the annual price tag of Bayer's pan-tumour drug Vitrakvi, boosting the saving to patients by $200,000.
In a statement released this morning, Butler said Vitrakvi would cost patients over $308,000 without subsidy yet Bayer has priced the medicine at around $100,000 per year.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.